Targets › CTAG2
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on CTAG2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Hadassah Medical Organization | HBI 0201-ESO TCRT Anti-NY-ESO-1 TCR-gene engineered lymphocytes | CTAG2 | Phase 1 | Sarcoma, Synovial | Dec 2027 |
Sarcoma, Synovial (1)
mixed (1)
Hadassah Medical Organization (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.